Form: SCHEDULE 13G/A

Statement of Beneficial Ownership by Certain Investors

February 17, 2026






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox checked   Rule 13d-1(b)
Checkbox not checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)






SCHEDULE 13G




Comment for Type of Reporting Person:  Includes (i) 618,397 shares of common stock, par value $0.0001 per share ("Common Stock") held by ADAR1 Partners, LP, (ii) 23,591 shares of Common Stock held by Spearhead Insurance Solutions IDF, LLC and (iii) 1,004,185 shares of Common Stock underlying prefunded and milestone warrants held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC as of December 31, 2025. Excludes 1,671,362 shares of Common Stock underlying prefunded and milestone warrants held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC, the exchange and exercise of which are subject to 9.99% beneficial ownership limitations. As the investment manager of ADAR1 Partners, LP and as the sub-advisor of Spearhead Insurance Solutions IDF, LLC, ADAR1 Capital Management, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC. Based on 15,474,026 shares of Common Stock of Grace Therapeutics, Inc. (the "Issuer") outstanding as of December 31, 2025, reported in the Issuer's Form 10-Q for the quarterly period ended December 31, 2025, filed with the Securities and Exchange Commission on February 12, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person:  Includes (i) 618,397 shares of common stock, par value $0.0001 per share ("Common Stock") held by ADAR1 Partners, LP and (iii) 1,030,394 shares of Common Stock underlying prefunded and milestone warrants held by ADAR1 Partners, LP as of December 31, 2025. Excludes 1,179,363 shares of Common Stock underlying prefunded and milestone warrants held by ADAR1 Partners, the exchange and exercise of which are subject to the 9.99% beneficial ownership limitations. As the general partner of ADAR1 Partners, LP, ADAR1 Capital Management GP, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP. Based on 15,474,026 shares of Common Stock of Grace Therapeutics, Inc. (the "Issuer") outstanding as of December 31, 2025, reported in the Issuer's Form 10-Q for the quarterly period ended December 31, 2025, filed with the Securities and Exchange Commission on February 12, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person:  Includes (i) 618,397 shares of common stock, par value $0.0001 per share ("Common Stock") held by ADAR1 Partners, LP, (ii) 23,591 shares of Common Stock held by Spearhead Insurance Solutions IDF, LLC and (iii) 1,004,185 shares of Common Stock underlying prefunded and milestone warrants held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC as of December 31, 2025. Excludes 1,671,362 shares of Common Stock underlying prefunded and milestone warrants held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC, the exchange and exercise of which are subject to 9.99% beneficial ownership limitations. As the manager of ADAR1 Capital Management, LLC and ADAR1 Capital Management GP, LLC, Mr. Schneeberger may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC. Based on 15,474,026 shares of Common Stock of Grace Therapeutics, Inc. (the "Issuer") outstanding as of December 31, 2025, reported in the Issuer's Form 10-Q for the quarterly period ended December 31, 2025, filed with the Securities and Exchange Commission on February 12, 2026.


SCHEDULE 13G



 
ADAR1 Capital Management, LLC
 
Signature:/s/ Daniel Schneeberger
Name/Title:Daniel Schneeberger, Manager
Date:02/17/2026
 
ADAR1 Capital Management GP, LLC
 
Signature:/s/ Daniel Schneeberger
Name/Title:Daniel Schneeberger, Manager
Date:02/17/2026
 
Daniel Schneeberger
 
Signature:/s/ Daniel Schneeberger
Name/Title:Daniel Schneeberger, in his individual capacity
Date:02/17/2026